Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Research unveils key gaps in continuity of care for sickle cell patients

Research unveils key gaps in continuity of care for sickle cell patients

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Infinity announces new data from IPI-145 Phase 1 trial on advanced hematologic malignancies

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

Ex-con gets arrested on purpose in order to get health care

Ex-con gets arrested on purpose in order to get health care

New assay test shows positive results for patients with recurrent or metastatic breast cancer

New assay test shows positive results for patients with recurrent or metastatic breast cancer

New hope for leukemia patients

New hope for leukemia patients

First Edition: December 10, 2012

First Edition: December 10, 2012

Vorinostat reduces risk of graft-vs.-host disease from bone marrow transplant treatments

Vorinostat reduces risk of graft-vs.-host disease from bone marrow transplant treatments

Ibrutinib may effectively combat chronic lymphocytic leukemia

Ibrutinib may effectively combat chronic lymphocytic leukemia

Angiocidin reduces acute myeloid leukemia cells in vivo by almost two-thirds in pre-clinical studies

Angiocidin reduces acute myeloid leukemia cells in vivo by almost two-thirds in pre-clinical studies

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

Targeting RAD52 protein can block the process by which leukemia stem cells repair themselves

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.